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Introduction {#sec005}
============

Since the era in which interferon (IFN) was the standard treatment for hepatitis C, attempts have been made to eliminate hepatitis C virus (HCV) following hepatocellular carcinoma (HCC) treatment, but it could be achieved in only a limited number of patients due to side effects. Recently, dramatic progress has been made in anti-HCV therapies. It is now feasible to achieve a sustained virological response (SVR) rate of ≥95% even in older patients or cirrhosis patients with IFN-free direct-acting antiviral (DAA) therapy that has minimal side effects in older patients and in cirrhosis patients \[[@pone.0194704.ref001]\], and antiviral therapy can now be performed easily in patients who have undergone HCC treatment. It has been reported that the elimination of HCV with IFN after curative treatment for HCV-associated HCC suppresses HCC recurrences \[[@pone.0194704.ref002]--[@pone.0194704.ref005]\]. We have also found that it dramatically extends patients' survival \[[@pone.0194704.ref006]\]. However, whether a similar effect can be achieved with DAA therapy is unclear. Furthermore, potential increases in unexpected early recurrence of HCC after HCV elimination have been reported with DAA therapy \[[@pone.0194704.ref007],[@pone.0194704.ref008]\]. With this background, the HCC recurrence rate was compared between those who underwent IFN therapy and those who underwent IFN-free therapy after HCC treatment in a large-scale cohort.

Methods {#sec006}
=======

Patients {#sec007}
--------

This was a multicenter study conducted by the Japanese Red Cross Hospital Liver Study Group consisting of 22 hospitals. This study investigated 516 patients who underwent antiviral therapy for hepatitis C after curative treatment for HCC. Antiviral therapy was given from 1999 to 2016, and all patients were followed for at least 24 weeks after antiviral therapy. The study was registered in UMIN (no. 000014971), and the research protocol was approved by the Ethics Review Board (Institutional Ethics Review Committee of Matsuyama Red Cross Hospital approval number: 422) of all participating institutions. All medications were open-label drugs. All parts of the research were conducted in accordance with the principles in the Declaration of Helsinki.

Antiviral treatment {#sec008}
-------------------

Of the 516 patients, 148 were treated by an IFN-containing regimen, and 368 were treated by an IFN-free DAA regimen. The IFN-containing regimen included IFN monotherapy (n = 6), Peg-IFN monotherapy (n = 24), IFN plus ribavirin (RBV) (n = 9), peg-IFN plus RBV (n = 57), and peg-IFN plus RBV plus protease inhibitor such as telaprevir, simeprevir, or vaniprevir (n = 52). The IFN-free DAA regimen included asunaprevir (ASV) plus daclatasvir (DCV) (n = 159), sofosbuvir (SOF) plus RBV (n = 51), paritaprevir/ombitasvir/ritonavir (n = 7), and SOF/ledipasvir (LDV) (n = 151). The mean follow-up period after antiviral therapy was 25.5 months for the IFN group and 7.7 months for the IFN-free DAA group.

Analysis of recurrence {#sec009}
----------------------

Factors associated with early recurrence that appeared within 24 weeks of completing antiviral therapy were assessed in all registered patients. An identical analysis was also conducted in the subgroup of patients who achieved SVR. Furthermore, in SVR patients, recurrence during the entire observation period was analyzed, and the difference in the recurrence rate between the IFN group and the IFN-free DAA group was analyzed.

Statistical analysis {#sec010}
--------------------

JMP ver.13.1.0 was used for statistical analysis, and the Mann-Whitney U test and the χ^2^ test were used for comparisons between two groups. Logistic regression analysis was used to identify risk factors for early recurrence (within a half-year). A Cox proportional hazards model was used to extract risk factors for recurrence with no restrictions on the follow-up period. The Kaplan-Meier method was used for the HCC recurrence curves, and the log-rank test was used to compare groups. A value of p \< 0.05 was considered to indicate a significant difference.

Results {#sec011}
=======

Patients' characteristics {#sec012}
-------------------------

The IFN-free DAA group was older, consisted of more women, and had longer duration from the date of last HCC treatment to antiviral therapy, lower leukocyte count, lower hemoglobin level, lower platelet count, lower albumin level, and higher Fib-4 index. However, data that reflect the state of HCC, such as HCC stage and AFP level, were not different, and all other clinical data were also not different ([Table 1](#pone.0194704.t001){ref-type="table"}). SVR was achieved in 78/148 patients (52.7%) in the IFN group and 347/368 patients (95.4%) in the IFN-free DAA group ([Fig 1](#pone.0194704.g001){ref-type="fig"}).

10.1371/journal.pone.0194704.t001

###### Baseline patient characteristics.

![](pone.0194704.t001){#pone.0194704.t001g}

  ------------------------------------------------------------------------------------------------------------------------------------------------
                                                                                                IFN group\          IFN-free group\     p value
                                                                                                (n = 148)           (n = 368)           
  --------------------------------------------------------------------------------------------- ------------------- ------------------- ----------
  Age (years) \[median (IQR)\]                                                                  66 (43--80)         73 (48--88)         \<0.0001

  Male:Female                                                                                   106:42              208:160             0.0013

  Number of days from previous HCC treatment to starting antiviral therapy \[median (range)\]   187 (4--3348)       333 (15--5038)      \<0.0001

  HCC Stage (I:II:III)                                                                          52:45:19            153:102:30          0.1585

  Leukocyte count (/μL) \[median (IQR)\]                                                        4420 (3635--5180)   3925(3100--5100)    0.0018

  Hemoglobin (g/mL) \[median (IQR)\]                                                            13.8 (12.6--14.7)   12.8 (11.6--14.0)   \<0.0001

  Platelet count (x10^4^/μL) \[median (IQR)\]                                                   12.5 (9.9--15.9)    10.2 (7.2--13.4)    \<0.0001

  ALT (IU/L) \[median (IQR)\]                                                                   53 (33--74)         44 (28--66)         0.0061

  Bilirubin (mg/dL) \[median (IQR)\]                                                            0.8 (0.6--1.1)      0.8 (0.6--1.1)      0.9447

  Protrombin time (%) \[median (IQR)\]                                                          84 (72--96)         83 (73--92)         0.7745

  Albumin (g/dL) \[median (IQR)\]                                                               4.0 (3.7--4.3)      3.8 (3.5--4.1)      0.0076

  Fibrosis-4 index \[median (IQR)\]                                                             3.8 (2.6--5.6)      5.6 (3.8--8.7)      \<0.0001

  α-fetoprotein (ng/mL) \[median (IQR)\]                                                        10 (6--20)          10 (5--23)          0.7550
  ------------------------------------------------------------------------------------------------------------------------------------------------

IFN: interferon, IQR: interquartile range, HCC: hepatocellular carcinoma, ALT: alanine aminotransferase.

![Flow sheet summarizing study selection.](pone.0194704.g001){#pone.0194704.g001}

Early recurrence of HCC {#sec013}
-----------------------

Factors associated with early recurrence that appeared within 24 weeks of completing antiviral therapy were analyzed in all registered patients. Univariate analysis showed that the type of antiviral therapy (IFN treatment or IFN-free DAA therapy), albumin, PT, AST, AFP at completion of antiviral therapy, duration from last HCC treatment to starting antiviral therapy, number of past treatments for HCC, clinical stage of HCC, and SVR status were significant factors. These factors were then subjected to multivariate analysis, which identified AFP at completion of antiviral therapy, clinical stage of HCC, and SVR status as independent factors. IFN-free DAA therapy was not identified as an independent factor that contributed to early recurrence within 24 weeks of antiviral therapy ([Table 2](#pone.0194704.t002){ref-type="table"}).

10.1371/journal.pone.0194704.t002

###### Factors associated with early recurrence of HCC within six months of completing antiviral therapy.
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  ---------------------------------------------------------------------------------------------------------------------------------------------------
  Factor                                                            Univariate analysis     Multivariate analysis                           
  ----------------------------------------------------------------- ----------------------- ----------------------- ----------------------- ---------
  Age (years)                                                       0.993 (0.969--1.018)    0.5826                                          

  Sex \[Male\]                                                      1.010 (0.662--1.551)    0.9639                                          

  IFN therapy \[Yes\]                                               1.544 (0.999--2.374)    0.0487                                          

  Previous treatment \[Yes\]                                        1.190 (0.746--1.906)    0.4672                                          

  Leukocyte count (/μL)                                             1.000 (1.000--1.000)    0.1014                                          

  Hemoglobin (g/mL)                                                 0.988 (0.884--1.106)    0.8348                                          

  Platelet count (x10^4^/μL)                                        0.959 (0.917--1.000)    0.0589                                          

  Albumin (g/dL)\                                                   0.565 (0.338--0.935)\   0.0274\                                         
  \<3.5 vs. ≥3.5 \[\<3.5\]                                          1.775 (1.051--2.965)    0.0323                                          

  Prothrombin time (%)\                                             0.981 (0.964--0.998)\   0.0282\                                         
  \<70 vs. ≥70 \[\<70\]                                             2.057 (1.137--3.666)    0.0176                                          

  AST (IU/L)\                                                       1.008 (1.002--1.015)\   0.0121\                                         
  \<63 vs. ≥63 \[≥63\]                                              1.729 (1.126--2.653)    0.0125                                          

  ALT (IU/L)                                                        1.005 (0.999--1.012)    0.0854                                          

  AFP; α-fetoprotein (ng/mL)                                        1.003 (1.000--1.006)    0.0634                                          

  DCP; des-γ-carboxy prothrombin (mAU/mL)                           1.003 (0.999--1.007)    0.1533                                          

  Fibrosis-4 index                                                  1.038 (0.995--1.085)    0.0878                                          

  HCV-RNA (LogIU/mL)                                                0.982 (0.745--1.312)    0.9014                                          

  ALT (end of treatment)                                            0.999 (0.990--1.004)    0.6839                                          

  AFP (end of treatment)\                                           1.024 (1.012--1.040)\   0.0003\                 1.021 (1.005--1.043)\   0.0321\
  \<9 vs. ≥9 \[≥9\]                                                 3.458 (2.186--5.504)    \<0.0001                3.487 (1.762--6.903)    0.0003

  Number of days from HCC treatment to starting antiviral therapy   0.999 (0.999--1.000)    0.0062                                          

  Number of treatments \[≥2\]                                       2.186 (1.399--3.440)    0.0006                                          

  Number of tumors \[\>3\]                                          1.742 (0.669--4.285)    0.2346                                          

  Tumor size \[\>3 cm\]                                             1.386 (0.643--2.854)    0.3867                                          

  Stage \[III\]                                                     2.458 (1.303--4.591)    0.0049                  2.526 (1.047--6.096)    0.0392

  SVR \[No\]                                                        0.411 (0.254--0.668)    0.0003                  3.943 (1.534--10.135)   0.0044
  ---------------------------------------------------------------------------------------------------------------------------------------------------

HCC: hepatocellular carcinoma, IFN: interferon, AST: aspartate aminotransferase, ALT: alanine aminotransferase, AFP: α-fetoprotein, DCP: des-γ-carboxy prothrombin, SVR: sustained virological response.

Analysis was repeated after obtaining a cutoff value for items that showed a significant difference with continuous variables. The area under the receiver operator characteristic curve (AUROC) for each item is shown in [Table 3](#pone.0194704.t003){ref-type="table"}.

10.1371/journal.pone.0194704.t003

###### AUROC for items for which cutoff values were set in [Table 2](#pone.0194704.t002){ref-type="table"}.
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  Factor \[Cutoff\]                      AUROC
  -------------------------------------- ---------
  Albumin (g/dL) \[3.5\]                 0.57547
  Prothrombin time (%) \[70\]            0.56937
  AST (IU/L) \[63\]                      0.56816
  AFP (end of treatment) (ng/mL) \[9\]   0.65736

Early recurrence of HCC in the SVR subgroup {#sec014}
-------------------------------------------

Since there was a large difference in the SVR rate between the IFN group and the IFN-free DAA group, factors associated with early recurrence within 24 weeks of completing antiviral therapy after HCC curative therapy were analyzed within the subgroup of patients who achieved SVR. Univariate analyses showed that albumin, PT, AST, Fib-4 index, AFP at completion of antiviral therapy, duration from last HCC treatment to starting antiviral therapy, number of past treatments for HCC, clinical stage of HCC, and number of HCC nodules were significant. However, the type of antiviral therapy (IFN treatment or IFN-free DAA therapy) was not a significant factor. Factors that were significant on univariate analysis were subjected to multivariate analysis, which identified clinical stage of HCC and the number of treatments as independent factors ([Table 4](#pone.0194704.t004){ref-type="table"}).

10.1371/journal.pone.0194704.t004

###### Factors associated with early recurrence of HCC within six months of completing antiviral therapy in patients who achieved SVR.
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  -------------------------------------------------------------------------------------------------------------------------------------------------
  Factor                                                            Univariate analysis     Multivariate analysis                          
  ----------------------------------------------------------------- ----------------------- ----------------------- ---------------------- --------
  Age (years)                                                       1.004 (0.975--1.034)    0.8055                                         

  Sex \[Male\]                                                      1.030 (0.629--1.706)    0.9064                                         

  IFN therapy \[Yes\]                                               1.023 (0.553--1.824)    0.9409                                         

  Previous treatment \[Yes\]                                        1.036 (0.614--1.747)    0.8941                                         

  Leukocyte count (/μL)                                             1.000 (1.000--1.000)    0.2433                                         

  Hemoglobin (g/mL)                                                 0.967 (0.850--1.103)    0.6150                                         

  Platelet count (x10^4^/μL)                                        0.970 (0.921--1.017)    0.2240                                         

  Albumin (g/dL)\                                                   0.542 (0.300--0.968)\   0.0398\                                        
  \<3.6 vs. ≥3.6 \[\<3.6\]                                          2.041 (1.181--3.505)    0.0109                                         

  Prothrombin time (%)\                                             0.971 (0.951--0.990)\   0.0042\                                        
  \<70 vs. ≥70 \[\<70\]                                             2.677 (1.401--5.042)    0.0032                                         

  AST (IU/L)\                                                       1.010 (1.002--1.018)\   0.0176\                                        
  \<63 vs. ≥63 \[≥63\]                                              2.177 (1.313--3.608)    0.0026                                         

  ALT (IU/L)                                                        1.003 (0.996--1.011)    0.3156                                         

  AFP (ng/mL)                                                       1.002 (0.999--1.005)    0.1370                                         

  DCP (mAU/mL)                                                      1.006 (1.001--1.014)    0.0733                                         

  Fibrosis-4 index                                                  1.031 (0.983--1.080)    0.1899                                         

  HCV-RNA (LogIU/mL)                                                0.927 (0.686--1.270)    0.6260                                         

  ALT (end of treatment)                                            0.996 (0.979--1.004)    0.4914                                         

  AFP (end of treatment)                                            1.018 (1.006--1.034)    0.0114                                         

  \<9 vs. ≥9 \[≥9\]                                                 2.667 (1.559--4.560)    0.0004                  2.340 (1.169--4.888)   0.0170

  Number of days from HCC treatment to starting antiviral therapy   0.999 (0.999--1.000)    0.0061                                         

  Number of treatments \[≥2\]                                       2.026 (1.202--3.451)    0.0085                                         

  Number of tumors \[\>3\]                                          2.010 (0.667--5.537)    0.1879                                         

  Tumor size \[\>3 cm\]                                             1.555 (0.642--3.511)    0.3033                                         

  Stage \[III\]                                                     2.289 (1.086--4.686)    0.0254                  3.089 (1.241--7.692)   0.0154
  -------------------------------------------------------------------------------------------------------------------------------------------------

HCC: hepatocellular carcinoma, SVR: sustained virological response, IFN: interferon, AST: aspartate aminotransferase, ALT: alanine aminotransferase, AFP: α-fetoprotein, DCP: des-γ-carboxy prothrombin.

The AUROC for each item is shown in [Table 5](#pone.0194704.t005){ref-type="table"}.

10.1371/journal.pone.0194704.t005

###### AUROC for items for which cutoff values were set in [Table 4](#pone.0194704.t004){ref-type="table"}.
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  Factor \[Cutoff\]                      AUROC
  -------------------------------------- ---------
  Albumin (g/dL) \[3.6\]                 0.58211
  Prothrombin time (%) \[70\]            0.60711
  AST (IU/L) \[63\]                      0.58842
  AFP (end of treatment) (ng/mL) \[9\]   0.61189

Recurrence of HCC throughout the observation period in the SVR subgroup {#sec015}
-----------------------------------------------------------------------

Factors associated with recurrence throughout the observation period, without restricting to 24-week early recurrence, were analyzed in SVR patients. Univariate analysis showed that platelets, albumin, PT, AST, ALT, Fib-4 index, AFP at completion of antiviral therapy, duration from last HCC treatment to starting antiviral therapy, number of past treatments for HCC, and number of HCC nodules were significant. However, the type of antiviral therapy (IFN treatment or IFN-free DAA therapy) was not a significant factor. On multivariate analysis, AFP at completion of antiviral therapy and duration from last HCC treatment to starting antiviral therapy were identified as independent factors ([Table 6](#pone.0194704.t006){ref-type="table"}). The AUROC for each item is shown in [Table 7](#pone.0194704.t007){ref-type="table"}. Kaplan-Meier analysis also did not demonstrate a significant difference between the IFN group and the IFN-free DAA group ([Fig 2](#pone.0194704.g002){ref-type="fig"}). Propensity scores were calculated with age, sex, FIB4, HCC stage, and the number of days from HCC treatment until the start of antiviral treatment as covariates, and propensity score matching (1:1) was performed ([Table 8](#pone.0194704.t008){ref-type="table"}). No differences were seen at the time in a comparison between the 2 groups of the HCC cumulative recurrence rate ([Fig 3](#pone.0194704.g003){ref-type="fig"}).

10.1371/journal.pone.0194704.t006

###### Factors associated with recurrence of HCC after completing antiviral therapy in patients who achieved SVR.
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  -------------------------------------------------------------------------------------------------------------------------------------------------
  Factor                                                            Univariate analysis     Multivariate analysis                          
  ----------------------------------------------------------------- ----------------------- ----------------------- ---------------------- --------
  Age (years)                                                       1.001 (0.981--1.022)    0.9136                                         

  Sex \[Male\]                                                      1.120 (0.791--1.605)    0.5276                                         

  IFN therapy \[Yes\]                                               0.950 (0.605--1.445)    0.8148                                         

  Previous treatment \[Yes\]                                        0.908 (0.629--1.308)    0.6057                                         

  Leukocyte count (/μL)                                             1.000 (1.000--1.000)    0.4530                                         

  Hemoglobin (g/mL)                                                 0.977 (1.068--1.024)    0.6048                                         

  Platelet count (x10^4^/μL)\                                       0.964 (0.931--0.997)\   0.0333\                                        
  \<10 vs. ≥10 \[\<10\]                                             1.563 (1.035--2.361)    0.0337                                         

  Albumin (g/dL)\                                                   0.558 (0.376--0.830)\   0.0041\                                        
  \<3.6 vs. ≥3.6 \[\<3.6\]                                          1.717 (1.080--2.723)    0.0226                                         

  Prothrombin time (%)\                                             0.974 (0.961--0.988)\   0.0002\                                        
  \<70 vs. ≥70 \[\<70\]                                             2.683 (1.513--4.759)    0.0008                                         

  AST (IU/L)\                                                       1.010 (1.005--1.014)\   0.0002\                                        
  \<63 vs. ≥63 \[≥63\]                                              2.472 (1.603--3.827)    0.0008                                         

  ALT (IU/L)\                                                       1.007 (1.002--1.011)\   0.0059\                                        
  \<55 vs. ≥55 \[55\]                                               1.895 (1.247--2.881)    0.0028                                         

  AFP (ng/mL)                                                       1.001 (1.000--1.003)    0.1223                                         

  DCP (mAU/mL)                                                      1.001 (0.999--1.002)    0.4164                                         

  Fibrosis-4 index                                                  1.036 (1.011--1.056)    0.0068                                         

  HCV-RNA (LogIU/mL)                                                0.961 (0.793--1.183)    0.6997                                         

  ALT (end of treatment)                                            1.000 (0.996--1.002)    0.8877                                         

  AFP (end of treatment)                                            1.001 (1.000--1.001)    0.0141                                         

  \<9 vs. ≥9 \[≥9\]                                                 3.428 (2.148--5.500)    \<0.0001                2.165 (1.305--3.564)   0.0030

  Number of days from HCC treatment to starting antiviral therapy   0.999 (0.999--1.000)    0.0097                  0.999 (0.999--1.000)   0.0270

  Number of treatments \[≥2\]                                       1.757 (1.237--2.506)    0.0138                  1.622 (1.012--2.617)   0.0444

  Number of tumors \[\>3\]                                          2.221 (1.119--3.981)    0.0466                                         

  Tumor size \[\>3 cm\]                                             1.076 (0.596--1.821)    0.7983                                         

  Stage \[III\]                                                     1.687 (0.996--2.710)    0.0517                                         
  -------------------------------------------------------------------------------------------------------------------------------------------------

HCC: hepatocellular carcinoma, SVR: sustained virological response, IFN: interferon, AST: aspartate aminotransferase, ALT: alanine aminotransferase, AFP: α-fetoprotein, DCP: des-γ-carboxy prothrombin

10.1371/journal.pone.0194704.t007

###### AUROC for items for which cutoff values were set in [Table 6](#pone.0194704.t006){ref-type="table"}.
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  Factor \[Cutoff\]                      AUROC
  -------------------------------------- ---------
  Platelet count (x10^4^/μL) \[\<10\]    0.56172
  Albumin (g/dL) \[3.6\]                 0.56000
  Prothrombin time (%) \[70\]            0.61047
  AST (IU/L) \[63\]                      0.60616
  ALT (IU/L) \[55\]                      0.57519
  AFP (end of treatment) (ng/mL) \[9\]   0.64714

10.1371/journal.pone.0194704.t008

###### Patient characteristics after propensity score matching.
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  ------------------------------------------------------------------------------------------------------------------------------------------
                                                                                                IFN group\       IFN-free group\   p value
                                                                                                (n = 56)         (n = 56)          
  --------------------------------------------------------------------------------------------- ---------------- ----------------- ---------
  Age (years)                                                                                   66.0±6.7         66.6±9.1          0.7158

  Male:Female                                                                                   42:14            41:15             0.8292

  Number of days from previous HCC treatment to starting antiviral therapy \[median (range)\]   194 (41--2667)   142 (22--1630)    0.0750

  HCC Stage (I : II : III)                                                                      21 : 26 : 9      22 : 27 : 7       0.8638

  Fibrosis-4 index \[median ± IQR\]                                                             3.77±1.86        3.79±1.34         0.4236
  ------------------------------------------------------------------------------------------------------------------------------------------

![Cumulative hepatocellular carcinoma (HCC) recurrence rate in patients who achieved sustained virological response.\
Kaplan-Meier analysis does not show a significant difference between the IFN group (gray line) and IFN-free DAA group (black line).](pone.0194704.g002){#pone.0194704.g002}

![HCC cumulative recurrence rate after propensity score matching.\
Kaplan-Meier analysis performed after matching also revealed no significant difference between the IFN group (gray line) and the IFN-free DAA group (black line).](pone.0194704.g003){#pone.0194704.g003}

Discussion {#sec016}
==========

In the present study using a multicenter study cohort, there was no difference in the early recurrence rate of HCC between patients who underwent IFN and those who underwent IFN-free DAA as antiviral therapies after curative HCC treatment. This is in contrast with the previous reports that described potential increases in unexpected early recurrence of HCC after HCV elimination with DAA therapy \[[@pone.0194704.ref007],[@pone.0194704.ref008]\]. The present data have a strength in that they were derived from a multicenter study that reflects the real-world data in Japan.

The SVR rate was as high as 94.3% in the IFN-free DAA-treated patients who had previously undergone HCC treatment. There is no doubt that IFN-free DAA therapy could be the standard antiviral treatment in terms of viral cure. However, the question remains whether DAA therapy in patients with a past history of HCC could be justified in terms of cost-effectiveness or improvement of survival. One of the major concerns is that the suppression of de novo HCC or recurrence of HCC may be weaker in IFN-free DAA regimens than in IFN-containing regimens.

In contrast to DAA that simply blocks HCV replication, treatments containing IFN are supposed to suppress HCV replication, to eliminate HCV-infected hepatocytes via immuno-stimulation, and to have an anti-tumor effect \[[@pone.0194704.ref009]\]. Therefore, there may be differences in recurrence-suppressing effects when SVR is achieved with an IFN-free DAA regimen vs. an IFN-containing regimen as postoperative adjuvant therapy after HCC treatment. In addition, there have been recent reports indicating that the recurrence rate may be increased after DAA therapy \[[@pone.0194704.ref008],[@pone.0194704.ref009]\], as well as reports that contradict this \[[@pone.0194704.ref010]--[@pone.0194704.ref013]\]. A theoretical background for this increased recurrence rate may be that patients develop an immune dysfunction immediately following HCV eradication \[[@pone.0194704.ref014],[@pone.0194704.ref015]\]. This can also be postulated based on reports of HBV re-activation that occurs during or immediately after DAA therapy \[[@pone.0194704.ref016]--[@pone.0194704.ref018]\]. The disappearance of hepatic lymphocyte infiltration associated with hepatitis eradication from the liver, as well as decreases in endogenous IFN secretion, may be involved in this pathway.

Despite these theoretical concerns about the reduced efficacy of recurrence suppression by IFN-free DAA regimens, the present study showed that the early recurrence rate of HCC was not different between patients who underwent IFN and those who underwent IFN-free DAA treatment. In the current investigation, the IFN-free DAA group was significantly older and included more patients with advanced fibrosis. This indicates that the IFN-free DAA group included more patients with a high risk of HCC recurrence. Nonetheless, there were no differences in the recurrence rate between IFN therapy and IFN-free DAA therapy in SVR patients. This suggests that achieving SVR with IFN-free DAA therapy has a similar or greater effect in suppressing HCC recurrence compared to achieving SVR with IFN therapy. Logistic regression and Cox proportional hazards model analysis identified factors associated with recurrence, such as HCC clinical stage, AFP at completion of antiviral therapy, and duration from last HCC treatment to starting antiviral therapy. These factors reflect the HCC in its original state, as well as after its treatment, indicating that the type of antiviral therapy did not contribute to its subsequent recurrence.

Although previous studies have shown that HCC recurrence was significantly suppressed with IFN in patients who achieved SVR compared to non-SVR patients, the HCC recurrence rate was still high after HCV elimination, indicating that HCV elimination cannot be an endpoint in the treatment of HCV-associated HCC \[[@pone.0194704.ref019]--[@pone.0194704.ref026]\]. This indicates that there is an extremely high carcinogenic potential in the non-cancerous portion of the liver in hepatitis C patients who have previously developed HCC. HCV elimination may improve liver function, leading to long-term survival in HCC patients, but it is not a sufficient condition for complete suppression of HCC recurrence. Establishing standard measures to suppress HCC recurrence after HCV eradication is desired. Furthermore, basic studies to assure the suppression of HCC recurrence after HCV elimination are also necessary.

While it is important to study the survival rate in patients who have undergone DAA therapy after HCC curative treatment, a sufficient observation period has not yet been achieved. In a previous study during the IFN era in which we assessed patients who had undergone IFN treatment for hepatitis C following HCC treatment, the survival rate was dramatically better in the SVR group than in the non-SVR group \[[@pone.0194704.ref006]\]. This improvement in survival rate occurred not only because mortality by liver failure was decreased due to improvement of liver function, but also because treatment options for HCC recurrence expanded as a result of improved hepatic reserve capacity, thereby enhancing curability. Therefore, an improvement in the survival rate can be fully anticipated in patients who achieve SVR with DAA therapy. While the survival benefit for patients treated by DAA should be examined in the future, it is primarily necessary to perform careful follow-up for HCC recurrence to achieve improvement of the survival rate.

There are several limitations to this study. First, this was a retrospective cohort study. Second, HCC curability and diagnosis of HCC recurrence were not strictly defined centrally and were determined by the attending physician. Third, because the duration of antiviral therapy differed depending on the regimen, there would have been a bias in either situation, whether the recurrence of HCC was counted from before starting the therapy or whether it was counted from after completing the therapy. However, understanding these limitations, we believe that this study has significant value in that it investigated numerous patients who were treated in actual clinical practice.

In conclusion, the HCC recurrence rate was compared between IFN therapy and IFN-free DAA therapy in patients who previously underwent curative treatment for HCC, and no differences were observed between the two groups. The outcomes of this study indicate that IFN-free DAA therapy can be recommended as an anti-HCV method following HCC treatment.
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